[HTML][HTML] Principles of clinical management of ovarian cancer
TV Gorodnova, AP Sokolenko, E Kuligina… - Chinese clinical …, 2018 - cco.amegroups.org
Epithelial ovarian cancer (EOC) is a common malignant disease, which remains
asymptomatic for a prolonged period of time and is usually diagnosed at advanced stages …
asymptomatic for a prolonged period of time and is usually diagnosed at advanced stages …
Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers
AP Sokolenko, EL Savonevich, AO Ivantsov, GA Raskin… - Cancer letters, 2017 - Elsevier
Ovarian carcinomas (OC) often demonstrate rapid tumor shrinkage upon neoadjuvant
chemotherapy (NACT). However, complete pathologic responses are very rare and the …
chemotherapy (NACT). However, complete pathologic responses are very rare and the …
Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients
AP Sokolenko, TN Sokolova, VI Ni… - Breast Cancer Research …, 2020 - Springer
Background The spectrum of BRCA1 and BRCA2 mutations in Slavic countries is
characterized by a high prevalence of founder alleles. Methods We analyzed a large data …
characterized by a high prevalence of founder alleles. Methods We analyzed a large data …
Endometrial cancer evolution: new molecular-biologic types and hormonal-metabolic shifts
LM Berstein, IV Berlev, AN Baltrukova - Future Oncology, 2017 - Future Medicine
The question hidden in the title of this manuscript (whether the topic develops or remains
constant) is important for all areas of science. It is also a serious problem for endometrial …
constant) is important for all areas of science. It is also a serious problem for endometrial …
ATL
TV Gorodnova, KB Kotiv, AO Ivantsov… - International Journal of …, 2018 - ijgc.bmj.com
Objectives Cisplatin and mitomycin C exert high activity towards BRCA1-deficient cells. This
study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1 …
study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1 …
[HTML][HTML] Detection of high-grade neoplasia in air-dried cervical PAP smears by a microRNA-based classifier
MK Ivanov, SE Titov, SA Glushkov… - Oncology …, 2018 - spandidos-publications.com
Recent studies have shown that changes in the expression levels of certain microRNAs
correlate with the degree of severity of cervical lesions. The aim of the present study was to …
correlate with the degree of severity of cervical lesions. The aim of the present study was to …
Features of endometrial cancer in patients with 'metabolically healthy'versus 'standard'obesity: the decreasing frequency of metabolically healthy obesity
LM Berstein, TE Poroshina, EA Turkevich… - Future Science …, 2015 - Future Science
Background: As endometrial cancer (EC) prevalence increases with obesity, we aimed to
determine whether EC characteristics depend upon obesity type:'standard'(SO) or …
determine whether EC characteristics depend upon obesity type:'standard'(SO) or …
[HTML][HTML] Detection of cervical lesions and cancer in air-dried cytologic smears by combined analysis of mRNA and miRNA expression levels
MK Ivanov, SE Titov, VV Dzyubenko… - The Journal of Molecular …, 2021 - Elsevier
Cervical cancer screening is based on cytologic analysis and high-risk human
papillomavirus (HR-HPV) testing, each having their drawbacks. Implementation of new …
papillomavirus (HR-HPV) testing, each having their drawbacks. Implementation of new …
[HTML][HTML] Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
TV Gorodnova, AP Sokolenko, KB Kotiv… - Hereditary Cancer in …, 2021 - Springer
Background Cisplatin, mitomycin C and anthracyclines demonstrate high activity in BRCA1-
deficient tumors. This study aimed to evaluate the efficacy of the triplet combination of these …
deficient tumors. This study aimed to evaluate the efficacy of the triplet combination of these …
Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer
TV Gorodnova, AP Sokolenko, SV Kondratiev… - Investigational New …, 2020 - Springer
Background Previous studies on neoadjuvant therapy for BRCA1-driven ovarian cancer
(OC) demonstrated higher efficacy of mitomycin C plus cisplatin combination as compared to …
(OC) demonstrated higher efficacy of mitomycin C plus cisplatin combination as compared to …